Related Experiment Video

Updated: Apr 13, 2026

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.9K

Novel targeted therapies for resistant ALK-rearranged non-small-cell lung cancer: ceritinib and beyond

Zeyad Kanaan1, Goetz H Kloecker1, Ajit Paintal2

  • 1Division of Medical Oncology and Hematology, James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA.

Oncotargets and Therapy
|May 7, 2015
PubMed

Insights

Lung cancer remains a leading cause of death. Second-generation ALK inhibitors like ceritinib show promise for patients with non-small-cell lung cancer who develop resistance to first-generation treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Lung cancer, particularly non-small-cell lung cancer (NSCLC), has dismal survival rates, especially in metastatic stages.
  • Targeted therapies focusing on driver mutations, such as anaplastic large-cell kinase (ALK) gene rearrangements, have emerged.
  • Resistance to first-generation ALK inhibitors like crizotinib is a significant clinical challenge, with progression typically occurring within 9 months.

Purpose of the Study:

  • To evaluate the efficacy of second-generation ALK inhibitors in NSCLC patients resistant to crizotinib.
  • To explore novel therapeutic strategies for overcoming acquired resistance to ALK-targeted therapies.
  • To identify potential treatment options for patients with advanced NSCLC and ALK rearrangements.

Main Methods:

  • Review of clinical trial data for ALK-inhibitor treated NSCLC patients.
  • Analysis of response rates and progression-free survival in patients treated with ceritinib.
  • Investigation of emerging therapeutic agents targeting alternative pathways in ALK-rearranged NSCLC.

Main Results:

  • Ceritinib demonstrates clinical activity in patients who have progressed on crizotinib.
  • Second-generation ALK inhibitors represent a promising treatment option for crizotinib-resistant NSCLC.
  • Ongoing research is exploring novel agents to address further resistance mechanisms.

Conclusions:

  • Targeted therapy for ALK-rearranged NSCLC has evolved, with newer agents showing efficacy against resistance.
  • Ceritinib offers a viable treatment alternative for patients progressing after crizotinib therapy.
  • Continued development of novel ALK inhibitors and combination strategies is crucial for managing advanced NSCLC.
Keywords:
ALK inhibitorEML4-ALK rearrangementVysiscrizotinib

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

543
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
131
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69